As­traZeneca to dis­con­tin­ue rare blood can­cer drug in the US

As­traZeneca is re­tir­ing Lu­mox­i­ti, its third-line treat­ment for a rare type of blood can­cer called hairy cell leukemia (HCL), the com­pa­ny con­firmed to End­points News on Thurs­day.

The drug will be per­ma­nent­ly dis­con­tin­ued in the US as of Ju­ly 2023, in part due to com­pe­ti­tion from ri­vals, a spokesper­son said in an email. The de­ci­sion “does not re­flect any new con­cerns about the safe­ty or ef­fi­ca­cy” of Lu­mox­i­ti, but rather “an eval­u­a­tion of the uti­liza­tion” of the drug and “the avail­abil­i­ty of oth­er treat­ments that are more wide­ly pre­scribed.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.